Shingrix is likely to replace Merck & Co's Zostavax as the preferred shingles vaccine in the EU and US, following the GSK product’s approval in the US and recent positive opinion in the EU. Sales in major markets could approach $700m by 2025.
With US regulatory approval in hand and passage likely in Europe, GlaxoSmithKline PLC's Shingrix vaccine looks poised to displace Merck & Co. Inc.'s Zostavax (Zoster vaccine live, ZVL) in both regions for treating shingles in older people, analysts say.
The FDA last October approved Shingrix for the prevention of herpes zoster in adults at least 50 years of age...
Create an account to read this article
Already a subscriber?
Deal Snapshot: Skyhawk raised its first seed funding in 2018 and has funded its operations primarily through partnering fees to date, including its latest agreement with Merck KGaA.
Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. The feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. The feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.
In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.
